Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:24:33.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the number of patients to be included in a multicenter, open-label, phase II clinical trial assessing the efficacy of pembrolizumab in combination with eribulin for female patients with HR-positive/HER2-negative metastatic breast cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:17:46.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as informed consent, age, health status, and prior treatments. This change provides more comprehensive information for researchers and potential participants regarding who can join the study.
    Difference
    43%
    Check dated 2024-05-22T21:19:26.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:51:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.